Cereno Scientific to present preclinical data for drug candidates CS014 and CS585 at the ESC Congress 2023
Cereno Scientific (Nasdaq First North: CRNO B), a company developing innovative treatments for common and rare cardiovascular disease, today announced that two abstracts on the preclinical drug candidates CS014 and CS585, respectively, have been accepted as moderated ePoster presentations at the ESC Congress 2023 hosted by the European Society of Cardiology, in Amsterdam, Netherlands, on August 25-28, 2023.The abstract titled “HDAC inhibitor CS014 inhibits platelet activity, small and large vessel thrombosis while maintaining hemostasis in a dose-dependent manner”, was authored by M.